STI571

Known as: STI 571, STI-571 
 

Topic mentions per year

Topic mentions per year

1968-2016
05010015019682016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
Clinical studies have shown that the tyrosine kinase inhibitor STI571 effectively controls BCR-ABL-positive chronic myelogenous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
In clinical trials, the tyrosine kinase inhibitor STI571 has proven highly effective in reducing leukemic cell burden in chronic… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promising new therapeutic strategy… (More)
  • table 1
  • table 2
  • table 4
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Targeting the tyrosine kinase activity of BCR-ABL represents a very promising therapeutic strategy in chronic myeloid leukemia… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Mutations in the c-KIT receptor occur somatically in many sporadic Gastrointestinal Stromal Tumors (GIST), and similar mutations… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clinical trials for the… (More)
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is an attractive therapeutic strategy in chronic myelogenous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The 2-phenylaminopyrimidine derivative STI571 has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The tyrosine kinase activity of the Bcr/Abl oncogene is required for transformation of hematopoietic cells. The tyrosine kinase… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?